This trial will follow patients who have received cilta-cel to see if there are any delayed adverse events.
7 Primary · 6 Secondary · Reporting Duration: Up to 15 years
Experimental Treatment
228 Total Participants · 1 Treatment Group
Primary Treatment: Cilta-cel · No Placebo Group · Phase 4
Age 18+ · All Participants · 2 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:California | 100.0% |
18 - 65 | 100.0% |
University of California, San Francisco | 100.0% |
Met criteria | 100.0% |